The weekend's resignation announcement of FDA official Peter Marks hit biotech stocks on Monday and sent Wall Street into a frenzy of concern over the future of biopharma approvals in the near term.

eXoZymes Inc. is featured on the cover of the April issue of GEN Biotechnology with a paper introducing the term "exozymes" to clarify the concept of cell-free biomanufacturing, which produces ...